Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases

Journal of Immunology

Volumn 162, Issue 11, 1999, Pages 6671-6680

  Dobrzanski, Mark J ^a   Reome, Joyce B ^a   Dutton, Richard W ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; IMMUNOTHERAPY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOPHENOTYPING; INTERFERON TYPE II; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OVALBUMIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033152967     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Croft, M., L. L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715.
2. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T cell subsets. Curr. Opin. Immunol. 8:336.
3. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
4. Cerwenka, A., L. L. Carter, J. B. Reome, S. L. Swain, and R. W. Dutton. 1998. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J. Immunol. 161:97.
5. Noble, A., P. A. Macary, and D. M. Kemeny. 1995. IFN-γ and IL-4 regulate the growth and differentiation of CD8 T cells into subpopulations with distinct cytokine profiles. J. Immunol. 155:2928.
6. Sad, S., D. Kagi, and T. R. Mosmann. 1996. Perforin and Fas killing by CD8 T cells limit their cytokine synthesis and proliferation. J. Exp. Med. 184:1543.
7. Fowler, D. H., J. Breglio, G. Nagel, J. Eckhaus, and R. E. Gress. 1996. Allospecific CD8 Tcl and Tc2 populations in graft versus leukemia effect and graft versus host disease. J. Immunol. 157:4811.
8. Carter, L. L., and R. W. Dutton. 1995. Relative perforin-and fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 155:1028.
9. Greenberg, P. D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
10. Fowler, D. H., J. Breglio, G. Nagel, C. Hirose, and R. E. Gress. 1996. Allospecific CD4, Th1/Th2 and CD8, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol. Blood Marrow Transplant. 2:118.
11. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E. Chang. 1997. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity. J. Immunol. 159:664.
12. Le Gros, G., and F. Erard. 1994. Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8 T cells: their activation and effector functions. Curr. Opin. Immunol. 6:453.
13. Pawelec, G., A. Rehbein, E. Schlotz, and P. da Silva. 1996. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro. Cancer Immunol. Immunother. 42:193.
14. Maggi, E., R. Manetti, R. Annunziato, L. Cosmi, M. G. Giudizi, R. Biagiotti, G. Galli, G. Zuccati and S. Romagnani 1997. Functional characterization and modulation of cytokine production by CD8 T cells from human immunodeficiency virus-infected individuals. Blood 89:3672.
15. Ioannides, C. G., and T. L. Whiteside. 1993. T cell recognition of human tumors: implications for the molecular immunotherapy of cancer. Clin Immunol. Immunopathol. 66:91.
16. Cheever, M. A., and W. Chen. 1997. Therapy with cultured T cells: principles revisited. Immunol. Rev. 157:177.
17. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonistic peptides induce positive selection. Cell 76:17.
18. Sayers, T. J., A. D. Brooks, J. K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout. 1998. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol. 161:3957.
19. Tsujimura, K., T. Takahashi, S. Iwase, Y. Matsudaira, Y. Kaneko, H. Yagita, and Y. Obata. 1998. Two types of anti-thymus leukemia CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements. J. Immunol. 160:5253.
20. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897.
21. Krasagakis, K., C. Garbe, and C. C. Zouboulis, and C. E. Orfanos. 1995. Growth control of melanoma cells and melanocytes by cytokines. Cancer Res. 139:169.
22. Pardoll, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.
23. Ogasawara, M., and S. A. Rosenberg. 1993. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Cancer Res. 53: 3561.
24. Wong, L. H., I. Hatzinisiriou, R. J. Devenish, and S. J. Ralph. 1998. IFN-γ priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-γ resistant melanoma cells to type I IFNs. J. Immunol. 160:5475.
25. Barth, R. J., Jr., J. J. Mule, P. J. Spiess, and S. A. Rosenberg. 1991. Interferon-γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8 tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
26. Aruga, A., S. Shu, and A. E. Chang. 1995. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41:317.
27. Morisaki, T., D. L. Morton, A. Uchiyama, D. Yuzuki, A. Barth, D. S. Hoon. 1994. Characterization and augmentation of CD4 cytotoxic T cell lines against melanoma. Cancer Immunol. Immunother. 39:172.
28. + T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol. 155:5719.
29. Hagenbaugh, A., S. Sharma, S. M. Dubinett, S. H.-Y. Wei, R. Aranda, H. Cheroutre, D. J. Flowell, S. Binder, B. Tsao, R. M. Locksley, K. W. Moore, and M. Kronenberg. 1997. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185:2101.
30. Noffz, G., Z. Qin, M. Kopf, and T. Blackenstein. 1998. Neutrophils but not eosinophils are involved in growth suppression of IL-4 secreting tumors. J. Immunol. 160:345.
31. Masuda, Y., S. Mita, K. Sakamoto, T. Ishiko, and M. Ogawa. 1995. Suppression of in vivo tumor growth by the transfection of the IL-5 gene into colon tumor cells. Cancer Immunol. Immunother. 41:325.
32. Nagoshi, M., P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein. 1998. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J. Immunol. 160:334.
33. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
34. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
35. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301.
36. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. Science 272:60.
37. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, and C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:746.
38. Siveke, J. T., and A. Hamann. 1998. T helper 1 and T helper 2 cells respond differently to chemokines. J. Immunol. 160:550.
39. Sallusto, F., C. R. Mackay, and A. Lanzavecchia. 1997. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005.
40. Kagamu, H., and S. Shu. 1998. Purification of L-selectin-low cells promote the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.
41. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
42. Swain, S. L., M. Croft, C. Dubey, L. Haynes, M. P. Rogers, X. Zhang, and L. M. Bradley. 1996. From naive to memory T cells. Immunol. Rev. 150:1243.
43. Gajewski, T. F., D W. Lancki, R. Stack, and F. W. Fitch. 1994. "Anergy" of Th0 helper T lymphocytes induces downregulation of Th1 characteristics and a transition to a Th2-like phenotype. J. Exp. Med 179:481.
44. Ramsdell, F., M. S. Seaman, R. E. Miller, K. S. Picha, M. K. Kennedy, and D. H. Lynch. 1994. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol. 6:1545.
45. Zhang, X., T. Brunner, L. Carter, R. W. Dutton, P. Rogers, T. Sato, J. Reed, D. Green, and S. L. Swain. 1997. Unequal death in T helper cell Th1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185:1.
46. Walker, P. R., P. Saas, and P. Y. Dietrich. 1998. Tumor expression of Fas ligand (CD95L) and the consequences. Curr. Opin. Immunol. 10:564.
47. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gasman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2179.
48. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Liienard, J. C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implication for tumor immune escape. Science 274:1363.
49. Binder, D., M. F. van den Broek, D. Kagi, H. Bluethmann, J. Fehr, H. Hengarter, and R. Zinkernagel. 1998. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8 T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 187:1903.
50. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.
51. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
52. Bridgewater, J. A., and M. E. Gore. 1995. Biological response modifiers in melanoma. Br. Med. Bull. 51:656.
53. Boon, T., J. V. Snick, A. V. Pel, C. Uyttenhove, and M. Marchaud. 1980. Immunogenetic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte mediated cytolysis. J. Exp. Med. 152:1184.
54. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161:2187.
55. Fujiwara, H., and T. Hamaoka. 1995. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol. Res. 14:271.
56. Jager, E., M. Ringhoffer, J. Karbach, M. Arand, F. Oesch, and A. Knuth. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 cytotoxic T cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66:470.
57. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P. G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340.
58. North, R. J. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res. 45:1.
59. Mukherji, B., A. Guha, N. G. Chakraborty, M. Sivanandham, A. L. Nashed, J. R. Sporn, and M. T. Ergin. 1989. Clonal analysis and regulatory T cell responses against human melanoma. J. Exp. Med. 169:1961.
60. Ochoa, A. C., and D. L. Longo. 1995. Alterations of signal transduction in T cells from cancer patients. In: Important Advances in oncology. V. T. Devita, S. Hellman, and S. A. Rosenberg, eds. J. B. Lippincott Company, Philadelphia, p. 43.
61. Lai, P., H. Rabinowich, P. A. Crowley-Nowick, M. C. Bell, G. Mantovani, and T. L. Whiteside. 1996. Alterations in expression and function of signal transducing proteins in tumor-associated T and NK cells in patients with ovarian carcinoma. Clin. Cancer Res. 2:161.
62. Chen, L., P. S. Linsley, and K. E. Hellström. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.